Article by Lalita Panicker, Consulting Editor, Views and Editor, Insight, Hindustan Times, New Delhi There’s welcome news in the battle against the Ebola virus, an infectious disease that for years had almost no treatments or remedies. Outbreaks of the deadly Ebola virus flare up in parts of Africa almost every year, and they’re vicious. The …
Article by Lalita Panicker, Consulting Editor, Views and Editor, Insight, Hindustan Times, New Delhi The 2023 Nobel Prize in Physiology or Medicine has been jointly awarded to Katalin Karikó and Drew Weissman for their discoveries concerning nucleoside base modifications that enabled the development of effective mRNA vaccines against COVID-19 https://www.nobelprize.org/prizes/medicine/2023/press-release/ The discoveries by the two …
Article by Lalita Panicker, Consulting Editor, Views and Editor, Insight, Hindustan Times, New Delhi To the relief of biomedical research advocates, a US Senate spending panel has approved a modest budget increase of 2% for the National Institutes of Health (NIH). The bump to $47.8 billion roughly matches President Joe Biden’s request for the 2024 …
Article by Lalita Panicker, Consulting Editor, Views and Editor, Insight, Hindustan Times, New Delhi The pharmaceutical company Johnson & Johnson (J&J) in mid-July agreed to help make a therapy critical to fighting drug-resistant tuberculosis (TB) more widely available and affordable. J&J said it would allow competitors to market generic versions of the lifesaving drug, bedaquiline, …
Article by Lalita Panicker, Consulting Editor, Views and Editor, Insight, Hindustan Times, New Delhi Twelve countries across different regions in Africa are set to receive 18 million doses of the first-ever malaria vaccine over the next two years. The roll out is a critical step forward in the fight against one of the leading causes …
In a packed San Francisco conference room last Tuesday, upbeat company representatives and scientists presented detailed clinical trial data on the first Alzheimer’s treatment shown to clearly, albeit modestly, slow the disease’s normal cognitive decline. The antibody therapy has buoyed a field marked by decades of failures. Now, it appears to be on the cusp …
The pharmaceutical companies Biogen and Eisai last week announced that a monoclonal antibody treatment reduced cognitive decline by 27% in people with early stage Alzheimer’s compared with those on a placebo after 18 months. www.science.org/content/article/news-glance-ai-regulation-renewable-energy-and-alzheimer-s-therapy? Lecanemab belongs to a class of therapies that break down or inhibit build up of amyloid plaques in the brain, …
A new monoclonal antibody treatment for Alzheimer’s disease Read More »
Earlier this week, the pharmaceutical companies Biogen and Eisai announced encouraging results from a clinical trial for patients with Alzheimer’s disease: a monoclonal antibody treatment, called lecanemab, reduced cognitive decline by 27% in people with early-stage Alzheimer’s compared with those on a placebo after a year and a half. Outside observers say the trial could …
Monoclonal antibody marks first approved Alzheimer’s treatment in nearly twenty years Read More »
Health experts across the globe are signalling alarm as they begin reporting that Omicron BA.5, the coronavirus strain that is currently outpacing other variants in infection and has become the dominant strain in the United States (US) and abroad, has the ability to reinfect people within weeks of contracting the virus. Andrew Robertson, the chief …
Subscribe our newsletter to stay updated
Copyright © 2023 | Health Issues Africa | All rights reserved.
